65,437 trials
Rabies
Primary: The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL — 55; 58 Participants
Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Primary: Overall Response Rate — 13.5 percentage of participants
Healthy
Primary: Variation Ratio of Total Repeatability and Reproducibility Hemoglobin Measurements Using Rad-67. — 10 ratio of variance
Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Complete Response (CR) — 12 Participants
Osteoporosis
Primary: Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) — 5.54; 5.39 percent
Advanced Pancreatic Cancer
Primary: Safety and Tolerability. — 73; 35; 4; 0 participants
Kidney Failure · Quality of Life · Fluid Restriction
Primary: Total Score for Kidney-Disease Quality of Life Short Form v1.3 — 69.66; 66.12 score on a scale
Kidney Transplantation · Kidney Diseases · Kidney Failure
Primary: One Year Survival With a Functioning Graft — 97.6; 95.1 Percent of patients — p=0.467
Open Chest Wounds
Primary: Duration of Negative Pressure Wound Therapy (NWPT) — 8 Days
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants
Menopause · Hot Flashes
Primary: Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 — -4.2; -6.1; -7.2; -7.0 VMS per…
Opioid Use Disorder
Primary: Number of Participants With Adverse Events (AEs) — 7; 11; 3; 7 Participants
Melanoma · Non-small Sell Lung Cancer (NSCLC) · Triple Negative Breast Cancer
Primary: Phase l: The Exposure (AUC(0-336h)) After First Dose of Treatment at Cycle 3 (Each Cycle = 28 Days) — 270; 1150; 3110; 575 day*ug/mL
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Wilson Disease
Primary: Percentage Of Participants With Normalized Concentrations Of NCC — 85.7 percentage of participants